

**DAFTAR PUSTAKA**

- Abdulkareem IH. A Review on aetio-pathogenesis of breast cancer. *J Genet Syndr Gene Ther.* 2013; 4: 1-4.
- Agrawal AK, Jelen M, Rudnicki J, Grzebieniak Z, Zysko D, Kielan W. The importance of preoperative elevated serum levels of CEA and CA15-3 in patients with breast cancer in predicting its histological type. *Folia Histochem Cytobiol.* 2010; 48: 26-9.
- Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DSB. Direct serum assay for microRNA-21 concentration in early and advanced breast cancer. *Clinical Chemistry.* 2011; 57(1): 84-91.
- Ashariati A. Manajemen kanker payudara komprehensif. Edisi 1. Surabaya : Airlangga university press. 2019. p1-11.
- Badr FM. Potential role of miR-21 in breast cancer diagnosis and therapy. *JSM Biotechnol Bioeng.* 2016; 3(5): 1068-76.
- Checka CM, Chun JE, Scnabel FR *et al.* The Relationship of mamographic density and age : Implication for breast cancer screening. *AJR Am J Roentgenol.* 2012; 198: 292-295.
- Chen X, Ba Y, Ma L. Characterization of miRNAs in serum : a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res.* 2008; 18: 997–1006.
- Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, Arlt D, Rath M, Sohn C, Benner A, Junkermann H, Schneeweiss A, Burwinkel B. Circulating microRNAs in plasma as early detection markers for breast cancer. *Int J of Cancer.* 2013; 132: 1602-1612.
- Corcoran C, Friel AM, Duffy MJ, Crown J, O’Driscoll L. Intracellular and extracellular microRNAs in breast cancer. *Clinical Chemistry.* 2011; 57(2): 18-32.
- Couch, FJ, Nathanson KL, Offit K. Two decades after BRCA: Setting paradigms in personalized cancer care and prevention. *Science.* 2014; 343: 1466-1470.
- Fattah HIA, Mahmoud NH, Elzoghby DM, Matar M, El-Shaer IM. Clinical utility of circulating microRNA-21 in breast cancer. *Egyptian J of Hosp Med.* 2018; 71(4): 2950-2955.
- Fu SW, Chen L, Man YG. miRNA biomarkers in breast cancer detection and management. *Journal of Cancer.* 2011; 2(1): 116-124.

- Gao J, Zhang Q, Xu J, Guo L, Li X. Clinical significance of serum miR-21 in breast cancer compared with CA 15-3 dan CEA. *Clin J Cancer Res*. 2013; 25(6): 743-48.
- Gao Y, Cai Q, Huang Y, Li S, Yang H, Sun L, Chen K, Wang Y. MicroRNA-21 as a potential diagnostic biomarker for breast cancer patients : a pooled analysis of individual studies. *Oncotarget*. 2016; 7(23): 98-105.
- Hamam R, Ali AM, Alsaleh KA, Kassem M, Alfayez M, Aldahmash A, Alajez NM. MicroRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. *Scientific Reports*. 2016; 6(1): 1-7.
- Hamam R, Hamam D, Alsaleh KA, Kassem M, Zaher W, Alfayez M, Aldahmash A, Alajez NM. Circulating microRNAs in breast cancer : novel diagnostic and prognostic biomarkers. *Cell Death & Disease*. 2017; 8(1): 23-34.
- Han JG, Jiang DY, Zhang CH, Yang YM, Pang D, Song YN, Zhang GQ. A novel panel of serum miR-21, miR-155, miR-365, as a potential diagnostic biomarkers for breast cancer. *Ann Surg Treat Res*. 2017; 92(2): 55-66.
- Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Kerin MJ. MicroRNAs as novel biomarkers for breast cancer. *Journal of Oncology*. 2010; 2(15): 9-16.
- Iorio MV, Casalini P, Piovan C, Braccioli L, Tagliabue E. Breast cancer and microRNAs : therapeutic impact. *The Breast*. 2011; 53: 563-570.
- Jemal A, Bray F, Center MM, *et al*. Global cancer statistic. *CA Cancer J Clin*. 2011; 61: 69-90.
- Juwita, Ompusunggu HES, Nauphar D, Pardede SM, Lim H, Siregar Y. miR-21 ekspresi in grade I, II, III breast cancer. *Indonesian J of Med*. 2016; 1(1): 26-33.
- Juwita. microRNA-21, microRNA-155, microRNA-10B bagaimana perannya pada kanker payudara?. *J Kedokteran Syiah Kuala*. 2017. 17(2): 119-25.
- Kayani MR, Kayani MA, Malik FA, Faryal R. Role of miRNAs in breast cancer. *Asian Pacific J of Cancer Prev*. 2011; 12: 3175-79.
- Kementerian Kesehatan RI. Panduan Nasional Penanganan Kanker 2015. Kanker Payudara.
- Kementerian Kesehatan RI. Profil kesehatan Indonesia tahun 2012. <http://www.depkes.go.id/profil-kesehatanp-indonesia-tahun-2012.pdf>. diakses pada tanggal 20/02/2019.

- Kenemans P, Verstraeten RA, Verheijen RHM *et al.* Oncogenic pathways in hereditary and sporadic breast cancer. *Maturitas.* 2004; 49: 34–43.
- Kim YK. Extracellular microRNAs as biomarkers in human disease. *CMJ.* 2015; 51(2): 51-58.
- Kumar S, Keerthana R, Pazhanimuthu A, Perumal P. Over ekspresi of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patient. *Indian J of Biochemistry & Biophysics.* 2013; 50: 210-214.
- Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. *RNA Biology.* 2011; 8(5): 706-713.
- Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H, Horiguchi J. Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes, *Journal of Human Genetics.* 2017; 62: 15–24.
- Li XF, Xu JJ, Zhang QY. Establishment of real-time PCR for detecting serum microRNA-21 and its preliminary in breast cancer. *Chin J Lab Med.* 2011; 34: 920-925.
- Mar-AguilarF, Jorge A. Mendoza-Ramireza, Ismael Malag´on-Santiago, Perla K. Espino-Silvad, Sandra K. Santuario-Facioc, Pablo Ruiz-Floresd, Cristina Rodriguez-Padillab, Diana Res´endez-P´ereza. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. *Disease Markers.* 2013; 34: 163–169.
- Mehrgou A & Akouchekian M. Therapeutic impacts of microRNAs in breast cancer by their roles in regulating processes involved in this disease. *J Res Med Sci.* 2017; 22: 130-138.
- Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman KW, Peterson A, Noteboom J, O’Brriant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS. Circulating microRNAs as stable blood-based markers for cancer detection. *PNAS.* 2008; 105(30): 513-518.
- Ng EKO, Li R, Shin VY, Jin HC, Leung CP, Ma ES, Pang R, Chua D, Chu KM, Law SY, Poon RT, Kwong A. Circulating microRNA as spesific biomarkers for breast cancer detection. *PLOS One.* 2013; 8(1): 1-13.
- Pan X, Wang ZX, Wang R. MicroRNA-21 a novel therapeutic target in human cancer. *Cancer Biology & Therapy.* 2010; 10(12): 1224-32.
- Reid G, Kirschner MB, Zandwijk NV. Circulating microRNAs : association with disease and potential use as biomarkers. *Crit Rev Oncol Hematol.* 2010; 12(8): 1-16.

- Rietdorf S. Detection of microRNAs in circulating tumor cells. *Transl Cancer Res.* 2018; 7(2): 197-208.
- Sarvari G, Rani S, Bitla AR. Breast cancer diagnosis : role of biomarkers. *J Clin Sci Res.* 2017; 6(1): 225-36.
- Schwarzenbach H & Gahan PB. MicroRNA shuttle from cell-to-cell by exosomes and its impact in cancer. *Non-coding RNA.* 2019; 5: 1-22.
- Shao Y, Sun X, He Y, Liu C, Liu H. Elevated levels of serum tumor markers CEA and CA15-3 are prognostic parameters for different molecular subtypes of breast cancer. *PLoS One.* 2015; 10:13-18.
- Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. MicroRNA-21 mediated tumor growth oncogene. 2007; 26: 2799-2803.
- Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H, Hu C. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. *J Cancer Res Clin Oncol.* 2013; 139: 223-229.
- Selcuklu SD, Donoghue MTA, Spillane C. miR-21 as a key regulator of oncogenic processes. *Bio Soc Trans.* 2009; 37(4): 918-925.
- Tang Y, Zhou X, Ji J, Chen L, Cao J, Luo J, Zhang S. High expression levels of microRNA-21 and microRNA-210 predict unfavourable survival in breast cancer : a systemic review and meta-analysis. *Int J Biol Markers.* 2015; 30(4): 347-58.
- Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V. Challenge using circulating miRNAs as cancer biomarker. *Bio Med Res Int.* 2015; 15: 1-10.
- Toraih EA, Mohammed EA, Farrag S, Ramsis N, Hosny S. Pilot study of serum microRNA-21 as a diagnostic and prognostic biomarker in Egyptian breast cancer patients. *Mol Diagn Ther.* 2015; 19: 179-190.
- Torre L, Bray F, Siegel R, *et al.* Global cancer statistic. *Cancer J Clin.* 2015; 65(2): 87-108.
- Uehara M, Kinoshita T, Hojo T, *et al.* Long term prognostic study of carcinoembryonic antigen (CEA) and Carbohydrate antigen 15-3 (CA 15-3) in breast cancer. *Int J Clin Oncol.* 2008; 13: 447-451.
- Usmani A, Shoro AA, Memon Z, Hussain M, Rehman R. Diagnostic, prognostic, and predictive value of microRNA-21 in breast cancer patients, their daughters and healthy individuals. *Am J Cancer Res.* 2015; 5(8): 2484-90.

- Verma MS, Rogers S, Divi RL, Schully SD, Nelson S. Epigenetic research in cancer epidemiology : Trends, opportunities and challenges. *Cancer Epidemiol Prev Biomarkers*. 2014; 23: 223-233.
- Wang B & Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. *J Cancer Res Clin Oncol*. 2012; 138: 1659-1666.
- Wang Y, Zhang Y, Pan C, Ma F, Zhang S. Prediction of poor prognostic in breast cancer patients based on microRNA-21 expression : A meta-analysis. *PLoS One*. 2015; 10(2): 1-13.
- Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY.. microRNA-21 over ekspresi in human breast cancer is associated with advanced clinical stage, lymph node metastase, and patient poor prognosis. *RNA*. 2008; 14: 2348-2360.
- Yanwirasti, Harahap WA, Arisanty D. Evaluation of miR-21 and miR-10b expression of human breast cancer in west sumatra. *Pak J Biol Sci*. 2017. 20(4): 189-96.
- Zhu S, Wu H, Wu F, Wie D, Shang S, Mo YY. miR-21 targets tumor supressor genes in invasion and metastase. *J Cell Res*. 2008; 18: 350-59.
- Zhu R, Dong YH, Yu HL. Prognostic value of miR-21 in patients with breast cancer : a meta-analysis. *Int J Clin Exp Med*. 2016; 9(2): 2017-26.
- Zhang J, Jiang C, Shi X, Yu H, Lin H, Peng Y. Diagnostic value of circulating miR-155, miR-21, and miR-10b as promising biomarkers in human breast cancer. *Int J Clin Exp Patol*. 2016; 9(10): 10258-65.
- Zhang WZ, Li Y, Wu X. Value of combined detection of serum miR-21, miR-195 and miR-222 in the diagnosis of early breast cancer. *Journal of Hainan Medical University*. 2016; 22(14): 128-130.
- Zhao H, Shen J, Medico L, Wang D, Ambrosone CB and Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. *PLoS One*. 2010;5: 5-11.